Tselios K, et al. - Researchers used an inception cohort of the Toronto Lupus Clinic, with 10-year follow-up, to ascertain whether low disease activity (LDA), defined as a clinical Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≤2, maintained for 12 months, confers the same risk for damage accrual as complete remission following 2 years. The patients who had a SLEDAI-2K score of 0 (serology excluded) within the first 5 years of enrollment and was maintained for ≥10 years, were considered to have achieved prolonged clinical remission. Overall 10.1% and 18% of the participants showed prolonged clinical remission and LDA, respectively, and long-term follow-up revealed comparable outcomes, making sustained LDA an acceptable treat-to-target outcome in SLE.